ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

2017 American Transplant Congress » Concurrent Session: Novel Immunosuppression Regimens - Belatacept

Date: Tuesday, May 2, 2017

Time: 4:30pm-6:00pm

Location: E354b

Session Type: Concurrent Session

Meeting: 2017 American Transplant Congress

4:30pm-4:42pm
Experience with Belatacept (CTLA4-Ig) Conversion in Highly HLA Sensitized (HS) and ABO-Incompatible (ABOi) Patients Who Received Incompatible Kidney Transplants Post Desensitization (DES).

J. Choi,1 A. Peng,1 A. Vo,1 E. Huang,1 R. Najjar,1 S. Louie,1 A. Kang,1 S. Ge,1 M. Toyoda,1 X. Zhang,2 S. Jordan.1

4:42pm-4:54pm
Belatacept Conversion for Calcineurin Inhibitor (CNI) Toxicity: Our First 100 Patients.

R. Crew, S. Patel, A. Pai, I. Batal, H. Fernandez.

4:54pm-5:06pm
IL-7 Receptor Heterogeneity as a Mechanism for Repertoire Change During Post-Depletional Homeostatic Proliferation and Its Relation to Costimulation Blockade Resistant Rejection.

H. Xu, T. Brennan, A. Kirk.

5:06pm-5:18pm
A Novel Belatacept Regimen to Optimize Efficacy and Safety.

D. Wojciechowski,1 S. Chandran,2 M. Sarwal,2 J. Yang,2 F. Vincenti.2

5:18pm-5:30pm
Stability of Immune Phenotype, Alloreactive, and Antiviral Immunity After Switch to Belatacept-Based Regimen After Kidney Transplantation.

J. Schaenman, M. Rosetti, T. Sidwell, V. Groysberg, G. Sunga, E. Liang, J. Gadzhyan, B. Abdalla, E. Lum, T. Pham, G. Dannovitch, J. Veale, H. Gritsch, E. Reed, S. Bunnapradist.

5:30pm-5:42pm
Impact of Belatacept Conversion on Kidney Transplant Function, Histology and Gene Expression.

P. Sanghi,1 G. Gupta,1 D. Kumar,1 J. Reeve,2 M. Levy,1 A. Sharma,1 H. Fattah,1 P. Kimball,1 H. Massey,1 A. King,1 P. Halloran.2

5:42pm-5:54pm
A Phase-Two, Randomised, Placebo-Controlled Trial: Belimumab in Renal Transplantation Targets Naïve, Activated Memory and Antibody Producing B Cells Whilst Sparing Regulatory B Cells.

G. Banham,1,2 S. Flint,3 N. Torpey,2 P. Lyons,1 D. Shanahan,3 A. Gibson,3 A.-M. O'Sullivan,2 R. Jones,1,2,3 L. Devey,3 A. Richards,3 L. Erwig,3 C. Savage,3 K. Smith,1,2 R. Henderson,3 M. Clatworthy.1,2

« View all sessions from the 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences